Abiopharma

Mereo BioPharma Group plc (NASDAQ MREO), (Mereo or the Company) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its investigational oral neutrophil elastase inhibitor, alvelestat (MPH-966) Mereo intends to have an End-of-Phase 2 meeting with the FDA to discuss the design of a registration-enabling study.